12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Deals

UMN Pharma, Ildong deal

On Dec. 18, 2012, UMN granted Ildong co-development and exclusive commercialization rights for influenza vaccines UMN-0502, UMN-0501 and UMN-0901 in Korea. UMN Pharma will receive an upfront payment and is eligible for milestones. UMN Pharma will manufacture and supply bulk vaccines for the final commercial...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >